Results 31 to 40 of about 72,644 (316)

Early Contrast Enhancement: a novel Magnetic Resonance Imaging biomarker of pleural malignancy [PDF]

, 2018
Introduction: Pleural Malignancy (PM) is often occult on subjective radiological assessment. We sought to define a novel, semi-objective Magnetic Resonance Imaging (MRI) biomarker of PM, targeted to increased tumour microvessel density (MVD) and ...
Alexander, Laura, Blyth, Kevin G., Cowell, Gordon W., Dick, Craig, Foster, John E., Humphreys, Catherine A., Kelly, Caroline A., Noble, Colin, Stobo, David B., Tsim, Selina, Woodward, Rosemary   +10 more
core   +1 more source

Is Adenosine Deaminase in Pleural Fluid a Useful Marker for Differentiating Tuberculosis from Lung Cancer or Mesothelioma in Japan, a Country with Intermediate Incidence of Tuberculosis? [PDF]

, 2011
The objective of this study was to evaluate the utility of the determination of adenosine deaminase (ADA) level in pleural fluid for the differential diagnosis between tuberculous pleural effusion (TPE) and malignant pleural effusion (MPE) in Japan, a ...
Aoe, Keisuke, Chikamori, Kenichi, Hiraki, Akio, Kishino, Daizo, Kiura, Katsuyuki, Maeda, Tadashi, Murakami, Kazuo, Ogata, Yoshiko, Tanimoto, Mitsune, Ueoka, Hiroshi   +9 more
core   +1 more source

CT in differential diagnosis of benign and malignant pleural disease

Monaldi Archives for Chest Disease, 2005
Background. CT plays a valuable role in assessment of patients with a wide variety of diseases of the pleura, and pulmonologists should be aware of the significance of different CT findings for the differential diagnosis of benign and malignant pleural ...
U. Yilmaz, G. Polat, N. Sahin, Ö. Soy, U. Gülay   +4 more
doaj   +1 more source

Multiplex Soluble Biomarker Analysis from Pleural Effusion

Biomolecules, 2020
Malignant pleural mesothelioma (MPM) is a highly aggressive and therapy resistant pleural malignancy that is caused by asbestos exposure. MPM is associated with poor prognosis and a short patient survival.
Joman Javadi, Katalin Dobra, Anders Hjerpe   +2 more
doaj   +1 more source

Assessment of the value of mesothelin in differentiating between different pleural malignancies by different interventional modalities

Egyptian Journal of Chest Disease and Tuberculosis, 2022
Context Malignant mesothelioma is an insidious neoplasm, with malignant pleural mesothelioma as the most common type, which is characterized by poor prognosis in most patients owing to late presentation. The use of noninvasive markers for early diagnosis
Mona M Ahmed, Gehan M El-Assal, Hesham A Abdel Halim, Rasha G.M. Mohamed   +3 more
doaj   +1 more source

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Cancer Discovery, 2018
Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining of the chest cavity. To expand our understanding of MPM, we conducted a comprehensive integrated genomic study, including the most detailed analysis of BAP1 alterations to date.
M. Ladanyi, P. Campbell, Bruce W. S. Robinson, J. Hmeljak, Ina Felau, F. Sánchez-Vega, A. Cherniack, J. Shih, K. Hoadley, Luda Danilova, R. Bowlby, G. Robertson, E. Gibb, R. Kanchi, Rehan Akbani, H. Osmanbeyoglu, Yulia Newton, Kiley Graim, David I Heiman, M. Noble, R. Shen, D. T. Severson, R. Bueno, L. Iype, V. Thorsson, David L. Gibbs, Lauren A. Byers, C. Gay, Lixia Dao, William D. Travis, S. Dacic, L. Chirieac, F. Galateau-Salle, J. Fujimoto, Aliya Husain, P. Desmeules, Achim A. Jungbluth, M. Zauderer, Anne S. Tsao, David J. Kwiatkowski, H. Kindler, H. Pass, J. Creaney, V. Rusch, R. Rintoul, T. Lichtenberg, Nathan Pennell, H. Silveira, G. Ravegnini, Jonathan A. Fletcher, H. Aburatani, Adrian Ally, Pavana Anur, J. Armenia, J. Auman, M. Balasundaram, S. Balu, Stephen B Baylin, C. Behrens, R. Beroukhim, C. Bielski, T. Bodenheimer, Moiz Bootwalla, Jay Bowen, Denise Brooks, Lauren A. Byers, F. Cárcano, Rebecca Carlsen, Andre L. Carvalho, Dorothy Cheung, Juok Cho, E. Chuah, Sudha Chudamani, C. Cibulskis, Leslie Cope, D. Crain, Erin E. Curley, Ludmila Danilova, A. Rienzo, T. DeFreitas, John A. Demchok, Noreen Dhalla, L. Diao, E. Drill, Michael Feldman, M. Ferguson, Jonathan A. Fletcher, Shiro Fukuda, S. Gabriel, F. G. Salle, Jianjiong Gao, J. Gardner, J. Gastier-Foster, C. Gay, Nils Gehlenborg, Mark Gerken, G. Getz, E. Gibb, C. Goparaju, Benjamin E. Gross, Guangwu Guo, Manaswi Gupta, Seiki Hasegawa, David Haussler, D. N. Hayes, David I Heiman, Zachary J. Heins, Robert A Holt, A. Hoyle, C. Hutter, S. Jefferys, Steven J.M. Jones, Corbin D. Jones, R. Kanchi, K. Kasaian, Jaegil Kim, N. Kondo, Thomas Krausz, Ritika Kundra, K. Kuribayashi, Phillip H. Lai, Peter W. Laird, Mike S. Lawrence, Darlene Lee, K. Leraas, T. Lichtenberg, Pei Lin, Jia Liu, Wenbin Liu, E. M. Liu, Laxmi Lolla, A. Longatto-Filho, Yiling Lu, Yussanne Ma, D. Maglinte, David Mallory, M. Marra, Michael Mayo, S. Meier, Jonathan Melamed, S. Meng, Matthew Meyerson, P. A. Mieczkowski   +142 more
semanticscholar   +1 more source

Malignant pleural mesothelioma

Annals of Oncology, 2006
Malignant pleural mesothelioma G. L. Ceresoli, G. P. Betta, B. Castagneto, F. Facciolo, G. Arcangeli, P. A. Zucali, R. Libener, D. De Giovanni, E. Melis & M. A. Mirri Department of Medical Oncology and Hematology, Istituto Clinico Humanitas IRCCS, Rozzano (MI); Pathology Unit, Department of Oncology, Azienda Sanitaria Ospedaliera, Alessandria ...
G. Arcangeli, G. P. Betta, E. Melis, R. Libener, Giovanni Luca Ceresoli, B. Castagneto, M. A. Mirri, D. De Giovanni, F. Facciolo, Paolo Andrea Zucali   +9 more
openaire   +3 more sources

Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting [PDF]

, 2019
The management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of ...
Girard, N, Grassino, M, Imbimbo, M, Maury, J, Vitale, F   +4 more
core   +1 more source

Survival prediction in mesothelioma using a scalable lasso regression model: instructions for use and initial performance using clinical predictors [PDF]

, 2018
Introduction: Accurate prognostication is difficult in malignant pleural mesothelioma (MPM). We developed a set of robust computational models to quantify the prognostic value of routinely available clinical data, which form the basis of published MPM ...
Blyth, Kevin G., Bylesjo, Max, Halligan, Daniel L., Kidd, Andrew C., McGettrick, Michael, Tsim, Selina   +5 more
core   +1 more source

Mesothelin and osteopontin as diagnostic and prognostic markers of malignant pleural mesothelioma in Egyptian patients undergoing pleurodesis

Egyptian Journal of Chest Disease and Tuberculosis, 2013
Purpose: In malignant pleural mesothelioma (MPM), early assessment of disease status is important. We evaluated the role of mesothelin and osteopontin biomarkers in distinguishing MPM from benign pleural disease. We also, evaluated whether mesothelin and
Fawzy M. Amany, Nagat Ali Mohamed, Reda El-Ghamry, Alaa Brik, Abdel Maged Salem, Amira Shoukry, Azza El-Sebaey   +6 more
doaj   +1 more source